Paper Details

  1. Home
  2. Paper Details

Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy--the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report. European Organization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative Hovon Group.

Author: ArchimbaudE, BernemanZ N, DekkerA W, FilletG, HaakH, HagemeijerA, HayatM, LöwenbergB, SolbuG, SonneveldP, StryckmansP, SuciuS, ThyssA, VisaniG, ZittounR, de CataldoR, van der LelieJ

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, U.S. Gov't, P.H.S.Research funding provided by the Public Health Service (PHS).

Overview

This study investigated different treatment approaches for older adults (over 60) with acute myeloid leukemia (AML). Two different chemotherapy regimens (daunomycin and mitoxantrone) were compared for achieving remission. After remission, patients were then randomly assigned to either receive additional chemotherapy or no further treatment.
Paper Details　
Original Abstract of the Article :
Optimization of remission-induction and postremission therapy in elderly individuals with acute myeloid leukemia (AML) was the subject of a randomized study in patients older than 60 years. Remission-induction chemotherapy was compared between daunomycin (DNR) 30 mg/m2 on days 1, 2, and 3 versus mit...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1200/JCO.1998.16.3.872

データ提供：米国国立医学図書館（NLM）

Optimizing Chemotherapy for Elderly Patients with Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a serious blood cancer, and finding effective treatments for elderly patients is a critical challenge. This study examines the effectiveness of different chemotherapy regimens and the role of low-dose cytarabine in remission maintenance for elderly patients with AML. The authors conducted a randomized controlled trial to compare different treatment approaches and identify factors that influence prognosis.

Tailoring Chemotherapy for Elderly Patients with AML

The research provides valuable insights into optimizing chemotherapy for elderly patients with AML. The study found that low-dose cytarabine can be effective in maintaining remission, suggesting that this approach might be particularly beneficial for older patients. The authors also identified several prognostic factors that can help predict treatment outcomes.

Navigating the Challenges of Cancer Treatment in Elderly Patients

This research underscores the importance of individualized treatment approaches for elderly patients with AML. Just as a desert caravan might choose different routes depending on the terrain, so too do oncologists need to tailor treatment plans to meet the unique needs of their patients. This study provides a valuable resource for clinicians seeking to optimize chemotherapy regimens and improve outcomes for elderly patients with this challenging disease.

Dr.Camel's Conclusion

This study emphasizes the importance of individualized care in cancer treatment. By understanding the nuances of different chemotherapy regimens and identifying key prognostic factors, we can provide more effective and personalized care to elderly patients with AML. This research offers hope for improving outcomes and ensuring the best possible care for vulnerable individuals.
Date :
  1. Date Completed 1998-03-24
  2. Date Revised 2017-02-10
Further Info :

Pubmed ID

9508168

DOI: Digital Object Identifier

10.1200/JCO.1998.16.3.872

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.